Melpomeni Fani

University Hospital Basel

Switzerland

Research Interests

Explore related searches

Professors in Switzerland

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (13)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (5)

Roger Schibli

Prof. at ETH Zürich

ETH Zürich

SWITZERLAND

View details

Jan Münch

GERMANY

View details

Piotr Garnuszek

associate professor

National Centre for Nuclear Research

POLAND

View details

Karim Alexandre Abid

Expert scientifique/head of the laboratory

University of Lausanne

SWITZERLAND

View details

Irene Virgolini

AUSTRIA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Melpomeni Fani

Research Interests

Explore related searches

Contact this professor

Articles (13)

Cover Feature: Improving Affinity while Reducing Kidney Uptake of CXCR4‐Targeting Radioligands Derived from the Endogenous Antagonist EPI‐X4 (ChemMedChem 6/2025)

Improving Affinity while Reducing Kidney Uptake of CXCR4‐Targeting Radioligands Derived from the Endogenous Antagonist EPI‐X4

First-in-human administration of terbium-161-labelled somatostatin receptor subtype 2 antagonist ([161Tb]Tb-DOTA-LM3) in a patient with a metastatic neuroendocrine tumour of the ileum

In-vivo inhibition of neutral endopeptidase 1 results in higher absorbed tumor doses of [177Lu]Lu-PP-F11N in humans: the lumed phase 0b study

Radiolabeled Somatostatin Receptor Antagonist Versus Agonist for Peptide Receptor Radionuclide Therapy in Patients with Therapy-Resistant Meningioma: PROMENADE Phase 0 Study

Copper-61 is an advantageous alternative to gallium-68 for PET imaging of somatostatin receptor-expressing tumors: a head-to-head comparative preclinical study

Development of the <sup>99m</sup>Tc-Labelled SST<sub>2</sub> Antagonist TECANT-1 for a First-in-Man Multicentre Clinical Study

Development of a New Class of CXCR4-Targeting Radioligands Based on the Endogenous Antagonist EPI-X4 for Oncological Applications

Comparison of 99mTc radiolabeled somatostatin antagonist with [<sup>68</sup> Ga]Ga-DOTA-TATE in a patient with advanced neuroendocrine tumor.

Early response monitoring during [177Lu]Lu-PSMA I&T therapy with quantitated SPECT/CT predicts overall survival of mCRPC patients: subgroup analysis of a Swiss-wide prospective registry study

<sup>61</sup>Cu-Labeled Radiotracers: Alternative or Choice?

CUDC-907, a dual PI3K/histone deacetylase inhibitor, increases meta-iodobenzylguanidine uptake (123/131I-mIBG) in vitro and in vivo: a promising candidate for advancing theranostics in neuroendocrine tumors

Head-to-head comparison of different classes of FAP radioligands designed to increase tumor residence time: monomer, dimer, albumin binders, and small molecules vs peptides

Collaborators (5)

Roger Schibli

Jan Münch

Piotr Garnuszek

Karim Alexandre Abid

Irene Virgolini

Make your next move.

Melpomeni Fani

Research Interests

Explore related searches

Contact this professor

Articles (13)

Cover Feature: Improving Affinity while Reducing Kidney Uptake of CXCR4‐Targeting Radioligands Derived from the Endogenous Antagonist EPI‐X4 (ChemMedChem 6/2025)

Improving Affinity while Reducing Kidney Uptake of CXCR4‐Targeting Radioligands Derived from the Endogenous Antagonist EPI‐X4

First-in-human administration of terbium-161-labelled somatostatin receptor subtype 2 antagonist ([161Tb]Tb-DOTA-LM3) in a patient with a metastatic neuroendocrine tumour of the ileum

In-vivo inhibition of neutral endopeptidase 1 results in higher absorbed tumor doses of [177Lu]Lu-PP-F11N in humans: the lumed phase 0b study

Radiolabeled Somatostatin Receptor Antagonist Versus Agonist for Peptide Receptor Radionuclide Therapy in Patients with Therapy-Resistant Meningioma: PROMENADE Phase 0 Study

Copper-61 is an advantageous alternative to gallium-68 for PET imaging of somatostatin receptor-expressing tumors: a head-to-head comparative preclinical study

Development of the <sup>99m</sup>Tc-Labelled SST<sub>2</sub> Antagonist TECANT-1 for a First-in-Man Multicentre Clinical Study

Development of a New Class of CXCR4-Targeting Radioligands Based on the Endogenous Antagonist EPI-X4 for Oncological Applications

Comparison of 99mTc radiolabeled somatostatin antagonist with [<sup>68</sup> Ga]Ga-DOTA-TATE in a patient with advanced neuroendocrine tumor.

Early response monitoring during [177Lu]Lu-PSMA I&amp;T therapy with quantitated SPECT/CT predicts overall survival of mCRPC patients: subgroup analysis of a Swiss-wide prospective registry study

<sup>61</sup>Cu-Labeled Radiotracers: Alternative or Choice?

CUDC-907, a dual PI3K/histone deacetylase inhibitor, increases meta-iodobenzylguanidine uptake (123/131I-mIBG) in vitro and in vivo: a promising candidate for advancing theranostics in neuroendocrine tumors

Head-to-head comparison of different classes of FAP radioligands designed to increase tumor residence time: monomer, dimer, albumin binders, and small molecules vs peptides

Collaborators (5)

Roger Schibli

Jan Münch

Piotr Garnuszek

Karim Alexandre Abid

Irene Virgolini

Make your next move.

Early response monitoring during [177Lu]Lu-PSMA I&T therapy with quantitated SPECT/CT predicts overall survival of mCRPC patients: subgroup analysis of a Swiss-wide prospective registry study